September 25, 2021

The Court of Appeal confirms the decision of the Liège Company Court thus allowing the reorganization plan of ASIT biotech to continue


ASIT biotech (ASIT – BE0974289218), a biopharmaceutical company under Judicial Reorganization Procedure (PRJ) announces today that the Liège Court of Appeal confirms the decision of the Liège company court approving the reorganization plan of ASIT biotech .

On April 16, 2021, ASIT signed a contribution in kind agreement with the company Diagnostic Medical Systems Group (Euronext Paris – FR0012202497 – DGM) under the terms of which DMS undertook to proceed, subject to the completion of a certain number of conditions to a contribution in kind of shares and current accounts of the medical imaging division for the benefit of ASIT (the “Bring »).

The Contribution was conditioned by the final approval of ASIT’s judicial reorganization plan. This condition precedent is now fulfilled.

Completion of the Contribution is also subject to (i) obtaining the approval of the shareholders of ASIT and DMS as well as the competent market authorities, (ii) obtaining the reports of the statutory auditors and auditors. whose mission is to assess the value of the Contribution and the fairness of the remuneration of the contributed assets, and (iii) carrying out the preliminary merger and contribution operations of the bone densitometry activity by DMS to APELEM.

DMS and ASIT continue to work with a view to completing the Contribution in the fall of 2021.


About ASIT biotech

ASIT biotech is a Belgian biopharmaceutical company at the clinical development stage specializing in the development and future commercialization of a new generation of immunotherapy products for allergies. More information on

Legal disclaimer

This press release does not in any way constitute an offer or an invitation to sell or issue, nor a solicitation of an offer to purchase or subscribe for shares of ASIT Biotech SA (the “Company” and the “Shares”). Any purchase, subscription or request for shares issued under the proposed offer should only be made on the basis of the information contained in the prospectus and any supplement thereto, if applicable. This press release does not constitute a prospectus and the information contained in this document is for informational purposes only and does not claim to be whole or complete. Investors should not subscribe to the Shares, except on the basis of the information contained in the prospectus which the Company intends to publish after its approval by the Belgian Financial Services and Markets Authority (the Financial Services and Markets Authority) and which may subsequently be obtained at the registered office of the Company and on the site This press release may not be distributed, directly or indirectly, in or to the United States or to any person in the United States within the meaning of the US Securities Act of 1933, as amended (the ” Securities Act ”). The Shares are not and will not be registered under the Securities Act and may not be offered or sold in the United States except on the basis of an exemption from the registration requirements under the Securities Act. The Company has not registered and does not intend to register any part of the proposed issue of the Shares in the United States, and does not intend to make a public offering of the Shares to the States. -United. This press release and the information it contains are not intended for publication, distribution or dissemination in or to the United States, Australia, Canada, Japan or any other jurisdiction in which the distribution, publication or the distribution of this press release would violate the laws and regulations in force. ASIT biotech assumes responsibility for the information contained in this press release.


Frank Hazevoets, CEO

ASIT biotech

Tel.: +32 (0) 471 56 35 33